论文部分内容阅读
目的 观察康莱特注射液对化疗失败的晚期非小细胞肺癌（ Ｎ Ｓ Ｃ Ｌ Ｃ）的疗效。方法 ３２ 例经顺铂加西艾克化疗失败的 Ｎ Ｓ Ｃ Ｌ Ｃ患者，给予康莱特注射液２００ ｍ ｌ，每天一次静滴，连用 ３０ 天。结果 部分缓解（ Ｐ Ｒ）８ 例（２５．０％ ），无效（ Ｎ Ｃ）２１ 例（６５．６％ ），进展（ Ｐ Ｄ）３ 例（９．４％ ）。 Ｋ Ｐ Ｓ评分，平均升高２０ 分。外周血 Ｔ 细胞亚群 Ｃ Ｄ３、 Ｃ Ｄ４、 Ｎ Ｋ 细胞升高， Ｃ Ｄ８ 下降， Ｃ Ｄ４／ Ｃ Ｄ８ 升高。多数病人治疗后精神，食欲、睡眠明显改善，疼痛减轻，疼痛缓解率为７５％ （１２／１６）。无化疗常见的胃肠道反应及骨髓抑制，不良反应轻微。结论 康莱特注射液治疗 Ｎ Ｓ Ｃ Ｌ Ｃ有一定疗效，并能提高患者的生活质量，可作为 Ｎ Ｓ Ｃ Ｌ Ｃ化疗失败后的补救治疗。
Objective To observe the effect of Kanglaite injection on chemotherapy-failed advanced non-small cell lung cancer (NSCLC). Methods Thirty-two patients with NSCLC C who failed chemotherapy with cisplatin plus cecil were given 200 ml of Kanglaite injection once a day for 30 days. Results Partial remission (P R) occurred in 8 patients (25.0%), invalid (NC) in 21 patients (65.6%), and progression (P D) in 3 patients (9.4%). The K P S score increased by an average of 20 points. Peripheral blood T cell subsets C D3, C D4, N K cells increased, C D8 decreased, C D4 / C D8 increased. Most patients had improved mental, appetite, sleep, pain relief, and pain relief rate of 75% (12/16). There was no common gastrointestinal reaction and bone marrow suppression with chemotherapy, and the adverse reactions were mild. Conclusion Kanglaite injection has certain curative effect on NSCLC, and can improve the quality of life of patients. It can be used as a remedy after NSCLC failure.